Skip to main content
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Sep;4(5):598–603. doi: 10.1128/cdli.4.5.598-603.1997

Synthetic-peptide-based enzyme-linked immunosorbent assay for screening human serum or plasma for antibodies to human immunodeficiency virus type 1 and type 2.

L Gonzalez 1, R W Boyle 1, M Zhang 1, J Castillo 1, S Whittier 1, P Della-Latta 1, L M Clarke 1, J R George 1, X Fang 1, J G Wang 1, B Hosein 1, C Y Wang 1
PMCID: PMC170605  PMID: 9302212

Abstract

A synthetic-peptide-based enzyme-linked immunosorbent assay (EIA) capable of screening for antibodies to both human immunodeficiency virus type 1 (HIV-1) and HIV-2 has been developed for use in blood banks and diagnostic laboratories. Microtiter wells are coated with two synthetic peptides, one corresponding to the highly conserved envelope region of HIV-1 and another corresponding to the conserved envelope region of HIV-2. Overall, sensitivity was 100% in 303 individuals diagnosed with AIDS and 96 individuals diagnosed with AIDS-related complex, 14.8% in a study of 500 high-risk group members, 99.9% in 600 EIA repeatedly reactive (RR)-HIV-1 Western blot (WB)-positive repository specimens, and 100% for 222 geographically diverse HIV-1 specimens and 216 confirmed HIV-2-positive specimens evaluated. The specificity was determined to be 99.72% for a total of 13,004 serum and plasma samples from random volunteer donors evaluated across five blood banks. Forty donors who were found to be EIA RR-WB indeterminate but nonreactive on the United Biomedical, Inc., test (UBI HIV 1/2 EIA) were prospectively followed as an additional measure of specificity. None of the 40 low-risk cases evolved into a positive WB pattern at follow-up. The sensitivity and specificity of this new assay are comparable to those of other Food and Drug Administration-licensed HIV-1 and HIV-1-HIV-2 assays that are currently available in the United States. The UBI HIV 1/2 EIA affords laboratories another choice in the detection of antibodies for HIV-1 and HIV-2 with a test based on an alternative antigen format.

Full Text

The Full Text of this article is available as a PDF (163.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Laurian Y., Paul D. A., Senn D. Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet. 1986 Nov 29;2(8518):1233–1236. doi: 10.1016/s0140-6736(86)92673-5. [DOI] [PubMed] [Google Scholar]
  2. Chang N. T., Chanda P. K., Barone A. D., McKinney S., Rhodes D. P., Tam S. H., Shearman C. W., Huang J., Chang T. W., Gallo R. C. Expression in Escherichia coli of open reading frame gene segments of HTLV-III. Science. 1985 Apr 5;228(4695):93–96. doi: 10.1126/science.2983429. [DOI] [PubMed] [Google Scholar]
  3. Dock N. L., Kleinman S. H., Rayfield M. A., Schable C. A., Williams A. E., Dodd R. Y. Human immunodeficiency virus infection and indeterminate western blot patterns. Prospective studies in a low prevalence population. Arch Intern Med. 1991 Mar;151(3):525–530. [PubMed] [Google Scholar]
  4. Gaines H., von Sydow M., Sönnerborg A., Albert J., Czajkowski J., Pehrson P. O., Chiodi F., Moberg L., Fenyö E. M., Asjö B. Antibody response in primary human immunodeficiency virus infection. Lancet. 1987 May 30;1(8544):1249–1253. doi: 10.1016/s0140-6736(87)92696-1. [DOI] [PubMed] [Google Scholar]
  5. Henderson L. E., Sowder R., Copeland T. D., Oroszlan S., Arthur L. O., Robey W. G., Fischinger P. J. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol. 1987 Feb;61(2):629–632. doi: 10.1128/jvi.61.2.629-632.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jackson J. B., MacDonald K. L., Cadwell J., Sullivan C., Kline W. E., Hanson M., Sannerud K. J., Stramer S. L., Fildes N. J., Kwok S. Y. Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. N Engl J Med. 1990 Jan 25;322(4):217–222. doi: 10.1056/NEJM199001253220402. [DOI] [PubMed] [Google Scholar]
  7. Kühnl P., Seidl S., Holzberger G. HLA DR4 antibodies cause positive HTLV-III antibody ELISA results. Lancet. 1985 May 25;1(8439):1222–1223. doi: 10.1016/s0140-6736(85)92910-1. [DOI] [PubMed] [Google Scholar]
  8. Leitman S. F., Klein H. G., Melpolder J. J., Read E. J., Esteban J. I., Leonard E. M., Harvath L., Shih J. W., Nealon R., Foy J. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med. 1989 Oct 5;321(14):917–924. doi: 10.1056/NEJM198910053211401. [DOI] [PubMed] [Google Scholar]
  9. Louwagie J., McCutchan F. E., Peeters M., Brennan T. P., Sanders-Buell E., Eddy G. A., van der Groen G., Fransen K., Gershy-Damet G. M., Deleys R. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 1993 Jun;7(6):769–780. doi: 10.1097/00002030-199306000-00003. [DOI] [PubMed] [Google Scholar]
  10. Sayers M. H., Beatty P. G., Hansen J. A. HLA antibodies as a cause of false-positive reactions in screening enzyme immunoassays for antibodies to human T-lymphotropic virus type III. Transfusion. 1986 Jan-Feb;26(1):113–115. doi: 10.1046/j.1537-2995.1986.26186124012.x. [DOI] [PubMed] [Google Scholar]
  11. Wang C. Y. Synthetic-peptide-based immunodiagnosis of retrovirus infections: current status and future prospects. Adv Biotechnol Processes. 1988;10:131–148. [PubMed] [Google Scholar]
  12. Wang J. J., Steel S., Wisniewolski R., Wang C. Y. Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proc Natl Acad Sci U S A. 1986 Aug;83(16):6159–6163. doi: 10.1073/pnas.83.16.6159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Zaaijer H. L., v Exel-Oehlers P., Kraaijeveld T., Altena E., Lelie P. N. Early detection of antibodies to HIV-1 by third-generation assays. Lancet. 1992 Sep 26;340(8822):770–772. doi: 10.1016/0140-6736(92)92303-w. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES